New sickle cell drug pociredir enters early human testing
NCT ID NCT07431398
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug called pociredir in 24 adults with sickle cell disease. Researchers want to see how the drug moves through the body and whether taking it with food changes its effects. The goal is to gather safety and dosing information, not to treat the disease itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Pharma - Miami
Miami, Florida, 33147, United States
-
Neuro-Behavioral Clinical Research
North Canton, Ohio, 44720, United States
-
Omega Research Group
Orlando, Florida, 32808, United States
-
Sonar Clinical Research
Riverdale, Georgia, 30274, United States
-
University of Texas Health Science Center Houston
Houston, Texas, 77030, United States
-
Worldwide Clinical Trials
San Antonio, Texas, 78217, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple screening test at birth save thousands of children with sickle cell disease?
- Can Eye-Tracking reveal hidden brain risks in babies with sickle cell disease?
- Can a peer coach help young people take control of their chronic illness?
- Could a stronger dose of an old drug protect children with sickle cell from organ damage?
- Gene editing could cure sickle cell by boosting fetal hemoglobin
- New stem cell processing method offers hope for patients without a perfect donor match